“Repeat-dose toxicology studies were conducted in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys given quizartinib dihydrochloride for up to 13 weeks.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Why that species
Cynomolgus monkey selected as alternate non-rodent based on PK and toxicology data
“Based on pharmacokinetic (PK) and toxicology data, the cynomolgus monkey was selected as a potential alternate nonrodent model for evaluating the toxicity profile of quizartinib to predict human safety risk.”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“Repeat-dose toxicology studies were conducted in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys given quizartinib dihydrochloride for up to 13 weeks.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗